Biotech
Triveni Bio
Triveni Bio raises $115M Series B at $550M valuation
$115M
Total Raised
Series B
Latest Round
2022
Founded
85+
Employees
Cambridge, MA
1 min read
Quick Facts
Valuation
$550M
Latest Round Size
$115M
Latest Round Date
October 2024
Triveni Bio: Series B Funding Round
Triveni Bio has successfully raised $115M in Series B funding, reaching a valuation of $550M.
Company Overview
Advancing preclinical antibody programs for immunological disorders
Funding Details
The Series B round was led by Lightspeed Venture Partners, with participation from GV.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2022
- Employees: 85+
- Category: Biotech
Investment
Triveni Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Lightspeed Venture Partners: Verified investor in Series B
- GV: Verified investor in Series B
Key Investors
Lightspeed Venture Partners
Lead Investor
Verified investor in Series B
GV
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M